He He

Dr. He He


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2025 in BMC Gastroenterology
Verified
Journal Article
Open access
PDF file
HYHuan Yang
Huan Yang
LLLibo Liang
Libo Liang
YLYan Liu
Yan Liu
XWXia Wang
Xia Wang
JLJinling Li
Jinling Li
HHHe He
He He
This study aimed to explore the association of red cell distribution width to albumin ratio (RAR) with all-cause mortality in ICU-NAFLD patients, to evaluate RAR as a prognostic tool. Patients were stratified into four groups, with 365- and 28-day all-cause mortality as primary and secondary endpoints. The Kaplan-Meier analysis compared survival across groups, while Cox regression and restricted cubic spline (RCS) evaluated associations between red cell distribution width-to-albumin ratio (RAR) and outcomes. The predictive performance of RAR was quantified using receiver operating characteristic (ROC) curves. A nomogram predicting treatment response was developed and internally validated via bootstrap resampling. Calibration and clinical utility were further assessed by Hosmer-Lemeshow test and decision curve analysis (DCA). A total of 590 patients with NAFLD were enrolled. Higher levels of the RAR index were correlated with an increased risk of 28- and 365-day all-cause mortality, as indicated by the K-M curves (log-rank P < 0.001). Multivariate Cox proportional risk analysis, after adjusting for confounding factors, displayed that high RAR levels were associated with an increased risk of 28-day mortality (HR 1.82[95%CI [1.10,3.04], P = 0.021) and 365-day mortality (HR 1.58 [95%CI[1.10,2.28], P = 0.014), with a nonlinear relationship observed for long-term risk (P-overall < 0.001, P-nonlinear = 0.046). Finally, the combination of RAR, TBiL, Scr, and INR had a good diagnostic efficiency for NAFLD (sensitivity: 72.93%, specificity: 69.44%, AUC: 0.759). The H-L test and DCA showed a certain alignment between predicted and actual results (accuracy of 0.733 and a Kappa statistic of 0.490). Elevated RAR independently predicts increased 28- and 365-day mortality in critically ill NAFLD patients. The combination of RAR with routine biomarkers (AUC = 0.759) improves mortality prediction. Routine monitoring of this simple, cost-effective ratio may aid in risk stratification and early intervention for high-risk ICU patients with NAFLD.

26 January 2025 in Clinica Chimica Acta
Verified
Journal Article
Closed access
XWXia Wang
Xia Wang
MZMei Zhang
Mei Zhang
CLChuan Li
Chuan Li
CJChengyao Jia
Chengyao Jia
XYXijie Yu
Xijie Yu
HHHe He
He He

4 October 2024 in Biomedicines
Verified
Journal Article
Open access
PDF file
SSShiya Shi
Shiya Shi
ZZZhouyanjie Zhou
Zhouyanjie Zhou
HZHe Zhang
He Zhang
YZYalan Zhu
Yalan Zhu
PJPengjun Jiang
Pengjun Jiang
JCjie chen
jie chen
Background: Observational studies have highlighted the pivotal role of inflammatory cytokines in cirrhosis progression. However, the existence of a causal link between inflammatory cytokines and cirrhosis remains uncertain. In this study, we conducted a bidirectional Mendelian randomization (MR) analysis at a summarized level to illuminate the potential causal relationship between the two variables. Methods: This study utilized genetic variance in cirrhosis and inflammatory cytokines from a genome-wide association study (GWAS) of European descent. The MR-PRESSO outlier test, Cochran’s Q test, and MR-Egger regression were applied to assess outliers, heterogeneity, and pleiotropy. The inverse variance weighted method and multiple sensitivity analyses were used to evaluate causalities. Furthermore, the validation set was used for simultaneous data validation. Results: The inflammatory cytokine monocyte chemoattractant protein 3 (MCP-3) was supposedly associated with a greater risk of cirrhosis. And cirrhosis was significantly correlated with increased levels of hepatocyte growth factor (HGF). Conclusions: This study suggests that MCP-3 might be associated with the etiology of cirrhosis, while several inflammatory cytokines could potentially play a role in its downstream development. Additionally, the progression of cirrhosis was associated with elevated levels of HGF, suggesting a possible role for liver repair functions.

10 March 2026 in Brain and Behavior
Verified
Journal Article
Open access
ZLZhi Liu
Zhi Liu
LLLibo Liang
Libo Liang
XDXiao Du
Xiao Du
HHHe He
He He
Background: Stroke has always been a huge medical challenge faced by China. Previous studies have found a negative correlation between high‐density lipoprotein cholesterol (HDL‐C) and stroke, but in recent years, with unsatisfactory drug experiments, researchers have begun to re‐examine this relationship. Our research is based on the large population of middle‐aged and elderly people in China, exploring the relationship between HDL‐C and stroke and all‐cause mortality. Methods: The participants of this study were from the China Health and Retirement Longitudinal Study (CHARLS) database. We utilized univariate/multivariate logistic regression to screen the influencing factors of stroke. Using Cox regression, we calculated the hazard ratio (HR) for stroke and mortality, presenting our findings through Kaplan–Meier (KM) curves. We also presented the relationship between HDL‐C and stroke and mortality by restricted cubic spline (RCS) regression analysis. A time‐varying Cox analysis was conducted to evaluate the impact of changes in HDL‐C on various outcomes. To strengthen the robustness and causal interpretation, we performed subgroup analysis, sensitivity analysis, and mediation pathway, and established a competing‐risk model. Results: HDL‐C was negatively correlated with stroke. After adjusting for confounders, HDL‐C remained a protective factor for stroke (HR 0.99, 95% CI 0.99–1.00, P  < 0.05), especially in the male group, the normal BMI group, the group without dyslipidemia, and the group with hypertension in the subgroup analysis. However, no significant association was observed between HDL‐C and all‐cause mortality after adjustment (HR 1.00, 95% CI 1.00–1.01, p = 0.482). The results remained robust in sensitivity analysis and competitive risk models. The impact of HDL‐C on the risk of stroke (HR 1.00, 95% CI 0.999–1.001, p = 0.887) and all‐cause mortality (HR 1.00, 95% CI 0.9995–1.001, p = 0.539) did not show a significant trend over time. Mediation analysis revealed that BMI mediated 25% of the effect of HDL‐C on stroke. Conclusions: In Chinese people over 45 years old, HDL‐C was a protective factor for stroke, while it had no significant association with all‐cause mortality. BMI mediated the effect of HDL‐C on stroke. This research highlights the critical role of HDL‐C in stroke risk assessment.

4 July 2025 in Biomedicines
Verified
Journal Article
Open access
PDF file
YZYuping Zeng
Yuping Zeng
XWXia Wang
Xia Wang
SLShenlin Liao
Shenlin Liao
CLChuan Li
Chuan Li
JCjie chen
jie chen
HHHe He
He He
Objectives: This study aimed to explore the mediating effects of iron homeostasis biomarkers linking central obesity with metabolic dysfunction-associated steatotic liver disease (MASLD) and primary liver cancer (PLC) via Mendelian randomization (MR) analysis. Methods: Two-sample bidirectional MR, multivariable MR, and mediation analyses were used to investigate the causal associations among obesity-related traits, iron homeostasis biomarkers, MASLD, and PLC. For the discovery and replication analyses, GWAS summary data for iron homeostasis biomarkers, MASLD, and PLC were extracted from two datasets, and the combined effects were pooled to corroborate the conclusions. Results: BMI and waist circumference were associated with a risk of MASLD in their combined effects (OR = 1.83, 95% CI = 1.33–2.52 for BMI; OR = 1.98, 95% CI = 1.63–2.41 for waist circumference). Waist circumference but not BMI had significant causal effects on the risk of PLC in the discovery dataset (OR = 1.71, 95% CI = 1.01–2.89 for BMI; OR = 2.72, 95% CI = 1.37–5.39 for waist circumference). In both of the iron homeostasis datasets, genetically predicted increased ferritin was associated with increased risk of MASLD by multivariable MR. We only observed that genetic liability to increased ferritin was associated with increased risk of PLC in iron homeostasis dataset 1 after adjusting for waist circumference. By two-step MR analysis, we found that genetic liability to ferritin mediated 3.34% (95% CI: 0.17–8.08%) of waist circumference effects on MASLD risk and 18.84% (95% CI: 3.01–40.51%) of its effects on PLC risk. Conclusions: Waist circumference and iron homeostasis biomarkers were causally associated with increased risks of MASLD and PLC. Central obesity may contribute to the development of MASLD and PLC by increasing ferritin levels.

30 October 2026 in Frontiers in Medicine
Verified
Journal Article
Open access
PDF file
CYChenyue Yan
Chenyue Yan
GZGuixiang Zhang
Guixiang Zhang
LLLibo Liang
Libo Liang
HHHe He
He He
Metabolic dysfunction-associated steatotic liver disease (MASLD) is a heterogeneous multisystem condition characterized by hepatic steatosis occurring in the context of metabolic dysfunction, and its prevalence continues to rise globally in parallel with the epidemics of obesity, type 2 diabetes, and metabolic syndrome. The heterogeneity of MASLD spanning etiology, pathophysiology, clinical presentation, and therapeutic response, poses substantial challenges for clinical management and underscores the need for a stratified approach to diagnosis and treatment. This review provides a comprehensive overview of MASLD heterogeneity, tracing the evolution of its classification from the exclusion-based NAFLD/NASH paradigm to the current positive-diagnosis MASLD framework with four principal subtypes: isolated MASLD, MetALD, MASH, and MASLD with other liver diseases. The multifactorial etiology of MASLD is examined, encompassing hepatic lobular spatial heterogeneity, lipid overload and inflammatory pathways, genetic and epigenetic determinants, and modifiable environmental risk factors. The heterogeneous clinical manifestations, including the distinct phenotypes of lean vs. obese MASLD and variable natural disease trajectories, are discussed. Diagnostic strategies are evaluated across the spectrum of disease severity, from non-invasive screening tools (MRI-PDFF, CAP, FIB-4, elastography) to histological assessment of MASH. Therapeutic approaches, including lifestyle modification, pharmacological therapies, and surgical interventions, are reviewed. Recognizing and systematically addressing this heterogeneity is essential for advancing precision medicine in this field. Based on subtype classification, risk factor profiling, and stage-appropriate diagnostic and therapeutic strategies, this review presents a stratification framework that offers clinicians a practical roadmap for delivering more personalized and effective care across the diverse spectrum of MASLD patients. In contrast to recent comprehensive reviews that provide broad overviews of MASLD, this review specifically addresses how disease heterogeneity should drive clinical decision-making, bridging the gap between subtype classification and personalized therapeutic selection.